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Abstract
Introduction:  Luffa  operculata  is  probably  one  of  the  most  popular  herbal  medicines  used  in
the treatment  of  rhinitis  and  rhinosinusitis.  However,  its  speciﬁc  mechanism  of  action  is  still
unknown.
Objective:  To  evaluate  in  vitro  antibacterial  activity  of  L.  operculata  against  three  ordinary
agents of  upper  respiratory  tract  infection:  Staphylococcus  aureus,  Streptococcus  pneumoniae
and Streptococcus  pyogenes.
Methods:  Different  concentrations  of  L.  operculata  alcoholic  extract  were  applied  to  bacterial
broth containing  reference  and  community  strains  of  the  three  described  agents.  After  a  24-h
incubation  period,  the  bacterial  culture  turbidity  was  measured.  The  samples  were  then  inoc-
ulated onto  Mueller-Hinton  and  human  blood  agar  plates.  Bacterial  growth  was  analyzed  after
24- and  48-h  incubation  period.  The  test  was  considered  negative  when  there  was  no  environ-
mental turbidity,  conﬁrmed  by  the  absence  of  bacterial  growth  into  the  inoculated  plates.  Tests
were considered  positive  when  either  turbidity  changes  were  observed  on  the  bacterial  broth
or when  bacterial  growth  was  detected  on  inoculated  plates.  Appropriate  statistical  analysis  of
the data  was  performed.
Results:  L.  operculata  extracts  showed  antibacterial  activity  mainly  to  S.  pyogenes  followed
by S.  pneumoniae  and  S.  aureus.
Conclusions:  L.  operculata  extract  showed  promising  antibacterial  activity  in  vitro  against  the
studied agents.
© 2014  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Published  by
Elsevier Editora  Ltda.  All  rights  reserved.
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Atividade  antimicrobiana  in  vitro  da  Luffa  operculata
Resumo
Introduc¸ão:  A  Luffa  operculata  é,  provavelmente,  o  ﬁtoterápico  mais  utilizado  no  tratamento
das rinites  e  rinossinusites.  Apesar  de  amplamente  utilizada  pela  populac¸ão,  seus  mecanismos
de ac¸ão  ainda  não  estão  completamente  estabelecidos.
Objetivo:  Avaliar  a  atividade  antimicrobiana  in  vitro  da  Luffa  operculata  em  agentes
causadores  de  infecc¸ões  de  vias  aéreas  superiores:  Staphylococcus  aureus,  Streptococcus  pneu-
moniae e  Streptococcus  pyogenes.
Método:  Foram  utilizadas  diferentes  concentrac¸ões  de  extrato  alcoólico  de  Luffa  operculata
em caldo  de  bactérias  dos  agentes  avaliados.  Após  incubac¸ão  de  24  horas  foi  realizada  a  leitura
de turvac¸ão  do  meio,  e  posteriormente,  semeadura  em  placas  de  ágar-sangue  e  ágar  Muller-
Hinton, após  24  e  48  horas  de  incubac¸ão.  Foram  considerados  testes  negativos  aqueles  em
que não  houve  a  turvac¸ão  do  meio,  conﬁrmados  pela  ausência  do  crescimento  das  bactérias
nas semeaduras.  Foram  considerados  positivos  os  testes  que  apresentaram  turvac¸ão  do  caldo
ou positividade  nas  semeaduras  de  24  ou  48  horas.  Os  resultados  foram  submetidos  à  análise
estatística  pertinente.
Resultados:  Os  extratos  de  Luffa  operculata  apresentaram  atividade  antimicrobiana,  especial-
mente para  Streptococcus  pyogenes,  seguido  dos  Streptococcus  pneumoniae  e  Sthaphylococcus
aureus.
Conclusões:  O  extrato  de  Luffa  operculata  apresentou  promissora  atividade  antimicrobiana
in vitro  contra  os  agentes  estudados.
©  2014  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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aIntroduction
The  widespread  use  of  antibiotics  to  treat  bacterial  rhinos-
inusitis,  besides  the  elimination  of  the  offending  organism,
aims  to  restore  the  normal  function  of  the  nasal  mucosa  and
the  paranasal  sinuses,  shortening  the  duration  of  symptoms
and  preventing  local  and  intracranial  complications.1
Although  widely  used,  antibiotics  are  not  the  only  thera-
peutic  option  for  rhinosinusitis.2 Adjuvant  treatments  should
be  used,  in  accordance  with  the  symptoms,  needs  and  lim-
itations  of  each  patient.  In  general,  nasal  washes  with
saline  solutions,  topical  and  systemic  corticosteroids,  anti-
histamines,  nasal  decongestants,  and  mucolytics,  among
others,  may  also  be  used.1--4
One  of  the  therapeutic  options  employed  by  a  large
portion  of  the  population  in  the  treatment  of  rhinosinusi-
tis  is  the  use  of  phytotheraphy,  or  herbalism.  Traditionally
used  by  the  poor  segment  of  the  Brazilian  rural  population,
especially  in  North,  Northeast  and  Midwest  regions  of  the
country,  herbal  medicine  has  been  used  increasingly  in  urban
centers  across  the  country,  by  patients  of  various  cultural
and  socioeconomic  levels.4
Among  the  medicinal  plants  used  informally  for  the  treat-
ment  of  rhinitis  and  rhinosinusitis,  Luffa  operculata, known
in  Brazil  as  ‘‘cabacinha’’  or  ‘‘buchinha-do-norte’’,  is  prob-
ably  the  most  commonly  used.5,6 L.  operculata  possesses  a
number  of  therapeutic  properties,  according  to  the  Brazil-
ian  population.  Although  several  studies  in  the  literature
sought  to  identify  the  mechanisms  by  which  L.  operculata
exhibits  such  properties,  no  evidence  of  antihistamine,  vaso-
constrictor,  anti-inﬂammatory,  or  antiviral  activity  of  this
O
T
ierbal  medicine  was  found.7--10 Structural  changes  in  the
espiratory  mucosa  were  described  by  experimental  stud-
es;  however,  the  concentration  and  the  way  in  which  L.
perculata  was  used  were  not  clearly  stated.4,11
In  a  recent  systematic  review  on  L.  operculata  effec-
iveness  in  the  clinical  treatment  of  rhinosinusitis,  it  was
oncluded  that  many  clarifying  scientiﬁc  data  on  the  subject
re  still  missing,  and  that  the  data  currently  available  are
till  very  controversial.12 Thus,  new,  insightful  and  reliable
tudies  are  in  order,  so  that  L.  operculata  can  be  used  safely
nd  effectively  in  the  treatment  of  sinonasal  diseases.12,13
In  an  attempt  to  elucidate  these  properties,  the  aim  of
his  study  was  to  evaluate  the  in  vitro  antimicrobial  activity
f  L.  operculata  against  some  causative  agents  of  rhinosi-
usitis.
ethods
he  study  was  conducted  in  the  Laboratory  of  Microbiol-
gy,  Department  of  Pathological  Sciences  and  Department
f  Otorhinolaryngology,  after  approval  of  the  relevant  Sci-
ntiﬁc  Committees.  The  Research  Ethics  Committee  of  the
nstitution  waived  the  evaluation  of  the  project,  because
here  is  no  involvement  of  human  beings  or  experimental
nimals.btaining  microorganisms
o  conduct  the  microbiological  assay,  specimens  of  clin-
cal  origin  were  selected  and  stored  in  the  Laboratory
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Table  1  McFarland  nephelometric  scale  with  the  estimated  number  of  bacteria  in  each  tube.
Tube  no.  0.5  1  2  3  4  5  6  7  8  9  10
Approximate  number  of  bacteria  (×108)  1.5  3  6  9  12  15  18  21  24  27  30
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tf  Microbiology  of  the  institution.  In  addition,  strains  of
merican  Type  Culture  Collection  (ATCC)  origin  were  also
elected.
ATCC  strains  are  standard  strains  with  a  known  suscep-
ibility  proﬁle  (i.e., they  have  a  serial  number  that  allows
s  to  know,  regardless  of  where  they  are  evaluated,  their
esponse  from  previously  tested  antibiotics),  thereby  ensur-
ng  the  reproducibility  of  the  study.
Despite  ATCC  strains  present  a  known  proﬁle,  it  is  not
ossible  to  evaluate  the  antimicrobial  activity  of  a  new
rug  without  also  using  strains  of  clinical  origin,  because
TCC  strains  do  not  represent  bacteria  causing  diseases
n  daily  life.  Strains  of  clinical  origin  are  necessary,  since
hey  have  different  susceptibility  proﬁles,  which  ensure
reater  ﬁdelity  for  the  evaluation  of  antimicrobial  action
ith  respect  to  those  organisms  of  interest.
ATCC  strains  may  be  sensitive  or  resistant.  Those  sensi-
ive  strains,  used  in  this  study,  show  sensitivity  to  antibiotics
sed  in  clinical  practice,  but  this  is  not  the  case  with  resis-
ant  strains.  Conceptually,  ATCC  strains,  when  presenting
esistance  to  two  or  more  classes  of  antimicrobials  to  which
hey  would  be  originally  sensitive,  are  classiﬁed  as  multi-
esistant  strains.
The  most  prevalent  etiologic  agents  of  bacterial  rhi-
usinusitis  are  Streptococcus  pneumoniae, Haemophilus
nﬂuenzae  and  Moraxella  catarrhalis; but  there  are  many
actors  involved  in  the  acquisition,  culture,  and  mainte-
ance  of  each  of  these  bacterial  organisms,  which  inﬂuenced
he  choice  of  agents  in  our  study.
H.  inﬂuenzae  and  M.  catarrhalis  are  fastidious  slow-
rowing  bacteria  that  require  special  culture  media  and
utrients  for  their  development.  This,  together  with  the  fact
hat  most  of  our  patients  who  had  cultures  sent  to  the  lab-
ratory  had  been  treated  with  antibiotics  prior  to  specimen
ollection,  resulted  in  the  isolation  of  only  a  few  strains  of
.  catarrhalis  and  H.  inﬂuenzae  during  the  26-month  period
f  establishing  our  bacterioteca.  Even  after  their  isolation,
ue  to  preservation  difﬁculties,  none  of  the  strains  remained
iable,  precluding  their  use  in  our  research.
Given  that  Staphylococcus  aureus, S.  pneumoniae  and
treptococcus  pyogenes  are  prevalent  in  upper  airway  infec-
ions  and  less  fastidious  bacteria  and  do  not  require  special
ulture  media  to  maintain  their  viability  and  growth,  these
rganisms  were  selected  for  this  study.
The  selection  of  the  strains  occurred  as  follows:
 S.  aureus  (25  strains):
1  ATCC-25923  sample  --  standard  strain,  with  a  known
sensitive  susceptibility  proﬁle.
24  isolates  of  clinical  origin  with  a  variable  susceptibil-
ity  proﬁle.
 S.  pneumoniae  (25  strains):
1  ATCC-49619  sample  --  standard  strain,  with  a  known
sensitive  susceptibility  proﬁle.
s
o
a
a24  isolates  of  clinical  origin  with  a  variable  susceptibil-
ity  proﬁle.
 S.  pyogenes  (25  strains):
1 ATCC-19615  sample  --  standard  strain,  with  a  known
sensitive  susceptibility  proﬁle.
24  isolates  of  clinical  origin  with  a  variable  susceptibil-
ity  proﬁle.
With  the  aid  of  a  sterilized  platinum  loop,  strains  of  S.
ureus,  S.  pneumoniae  and  S.  pyogenes  were  transferred
o  test  tubes  containing  10  mL  of  casein-peptone  soymeal-
eptone  broth,  i.e., Tryptic  Soy  Bean  (TSB),  an  environment
hat  allows  preservation  of  bacterial  viability.  Suspensions  of
he  microorganisms  were  standardized  by  their  comparison
o  0.5  in  a  McFarland  scale,  corresponding  to  approximately
.5  ×  108 CFU/mL  (Colony  Forming  Units  per  milliliter).
The  McFarland  scale  (Table  1) is  a  nephelometric  scale
f  11  tubes,  numbered  from  0.5  to  10;  its  turbidity  stan-
ard  is  the  most  often  used  in  microbiology  laboratories  in
razil  and  in  the  United  States  to  determine  the  intensity
f  bacterial  multiplication  in  liquid  culture  media.  The  bac-
erial  multiplication  precludes  the  passage  of  light,  which
auses  turbidity  and  opaciﬁcation  of  the  culture  medium.
he  greater  the  number  of  bacteria  present  in  the  sample,
he  greater  the  turbidity  of  the  culture  medium.  Recom-
ended  by  the  Clinical  and  Laboratory  Standards  Institute
CLSI),  United  States,  the  McFarland  nephelometric  scale
as  also  adopted  and  recommended  by  ANVISA  in  Brazil.14
ith  this  regulation,  it  is  possible  to  establish  a  standard
hat  can  be  gauged  at  any  location  in  the  country,  generating
orrespondence  in  the  reading  of  their  results.
btaining  concentrations  of  L.  operculata
he  evaluation  of  the  in  vitro  antimicrobial  activity  of  L.
perculata  with  respect  to  the  tested  agents  was  performed
y  the  broth  macrodilution  technique,  with  L.  operculata
oncentrations  of  0.2%;  0.3%;  0.4%;  0.5%;  1%  and  2%  in  TSB
ulture  medium.
An alcoholic  extract  of  L.  operculata  (Schraiber®),  batch
umber  5343,  with  125  mL,  alcohol  strength  of  65%,  with  L.
perculata  concentration  of  10%  was  used.  This  product  was
anufactured  on  October  6,  2010  with  validity  period  until
ctober  6,  2015.
For  obtaining  these  dilutions,  a  graded  pipette,  which
llowed  accurate  samplings  of  the  10%  alcoholic  extract  of
.  operculata, with  a  minimum  content  of  0.1  mL,  was  used,
s  well  as  sterile  and  dry  10-mL  test  tubes  for  solution.  Sev-
ral  10  mL  tubes  were  prepared  at  different  concentrations;
hese  tubes  were  used  as  needed,  with  no  need  to  keep  them
tored.  That  is  to  say,  a  new  test  tube  containing  TSB  and  L.
perculata, at  different  concentrations,  was  prepared  only
fter  the  previous  tube  was  ﬁnished.  Hence,  our  aim  was  to
void  any  contamination  from  their  storage  (Table  2).
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Table  2  Calculation  of  dilutions  from  the  initial  concentration  of  10%  alcoholic  extract  of  Luffa  operculata.
Concentrations  of  Luffa  operculata  (%)  Luffa  operculata  10%  (mL)  TSB  (mL)  Luffa  operculata  +  TSB  (mL)
0.2  0.2  9.8  10
0.3 0.3  9.7  10
0.4 0.4  9.6  10
0.5 0.5  9.5  10
1 1  9  10
2 2  8  10
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deemed  poor  when  p  <  0.4;  moderate,  when  0.4  <  p  <  0.6;
and  strong  when  p  >  0.6.  All  samples  were  performed  inTSB, Tryptic Soy Bean.
After  this  dilution,  1  mL  of  alcoholic  extract  in  several
concentrations  was  deposited  into  different  dry  and  ster-
ile  10  ×  1.5-cm  test  tubes.  Next,  1  mL  of  bacterial  broth
(concentration  of  0.5  McFarland,  which  corresponds  to
approximately  1.5  ×  108 CFU/mL)  was  deposited  in  these
test  tubes.  All  turbidity  tests,  24-  and  48-h  cultures,  and  con-
trols  were  performed  in  duplicate  for  all  concentrations,  and
controls  were  performed  in  duplicate  for  all  concentrations,
in  order  to  exclude  any  sample  contamination.
Controls
To  avoid  bias  in  the  interpretation  of  data,  three  sample  con-
trols  were  performed:  a  negative  control,  a  positive  control
and  an  alcoholic  control.
For  negative  control,  a  2-mL  tube  containing  L.  oper-
culata  was  used;  and  for  positive  control,  another  2-mL
tube  with  bacteria  broth  was  used.  These  tubes  were
taken  to  the  incubator,  where  they  were  incubated  at
about  37 ◦C  ±  2 ◦C  ×  24  h.  After  24  h,  a  tube  reading  was  per-
formed,  to  ascertain  whether  or  not  there  was  bacterial
growth,  which  was  indicated  by  the  occurrence  of  medium
turbidity.  All  tubes  were  plated  on  90-mm  blood  agar  plates
to  assess  growth  and  viability  of  S.  pneumoniae  and  S.  pyo-
genes,  and  on  150-mm  Mueller  Hinton  agar  plates  to  assess
growth  and  viability  of  S.  aureus.  Plate  reading  was  per-
formed  after  24  and  48  h.
With  respect  to  our  analysis  criteria,  tests  not  presenting
medium  turbidity  after  bacterial  inoculation  were  consid-
ered  negative,  and  this  was  conﬁrmed  by  the  absence  of
bacterial  growth  in  24-  and  48-h  inoculations.  Tests  exhibit-
ing  broth  turbidity  or  positivity  in  24-  and  48-h  inoculations
were  considered  positive  (Figs.  1  and  2).
The  simple  absence  of  turbidity  in  the  test  tubes  does
not  make  it  possible  to  assert  whether  or  not  there  was  bac-
terial  eradication  in  a  medium  containing  L.  operculata  and
in  bacterial  broth.  On  the  other  hand,  this  ﬁnding  allows  us
to  state  that  there  was  a  minimum  inhibitory  concentration
(MIC),  i.e., the  minimum  concentration  at  which  bacterial
growth  was  inhibited.  If  bacterial  growth  in  24-  and  48-h
inoculations  occurred,  this  suggests  that  a  greater  L.  oper-
culata  concentration  will  be  required  to  kill  all  bacteria.  On
the  other  hand,  when,  during  the  reading,  the  absence  of
turbidity  is  conﬁrmed  by  bacterial  growth  absence  in  24-  and
48-h  inoculations,  we  can  establish  the  minimum  bacterici-
dal  concentration  (MBC),  i.e., the  minimum  concentration
required  for  killing  all  bacteria.After  dilution  of  L.  operculata  extract  to  10%  and  with
n  alcoholic  content  of  65%  for  L.  operculata  extracts  at
oncentrations  of  0.2%;  0.3%;  0.4%;  0.5%;  1%  and  2%,  the
lcohol  content  of  the  same  concentrations  was  calculated
Table  3).
The  higher  alcoholic  content  found  was  13%  at  a  concen-
ration  of  2%  of  L.  operculata. To  conﬁrm  the  absence
f  antimicrobial  action  by  ethanol  in  these  different  con-
entrations,  ethanol  tubes  with  different  alcohol  strengths
between  1.35%  and  13%)  and  with  bacterial  broth  were
aken  to  the  incubator,  where  the  tubes  were  incubated
t  about  37 ◦C  ±  2 ◦C  ×  24  h.  After  24  h,  a  tube  reading  was
erformed  to  verify  whether  there  was  bacterial  growth,
ndicated  by  medium  turbidity;  culturing  of  all  tubes  on
0-mm  agar-blood  plates  was  performed  to  assess  S.  pneu-
oniae  and  S.  pyogenes  growth  and  viability.  We  did  the
ame  for  S.  aureus  on  150-mm  Muller-Hinton  agar  plates.
his  scheme  was  repeated  after  48  h  incubation.
To  assess  the  agreement  between  the  methods  of  turbid-
ty  and  of  24-  and  48-h  cultures,  the  Kappa  method,  which
ims,  by  a  measure  of  association,  to  establish  an  agree-
ent  between  qualitative  variables,  was  used.  Its  value  can
e  equal  to  zero,  or  non-zero.  When  a  non-zero  value  is
btained,  the  agreement  is  calculated.  The  agreement  isFigure  1  (A)  Presence  of  turbidity;  (B)  absence  of  turbidity.
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Figure  2  Muller-Hinton  agar  plates:  (A)  no  bacterial  growth;  (B)  with  bacterial  growth.  Blood-Agar  plates:  (C)  no  bacterial  growth;
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uplicate.  The  program  used  for  statistical  analysis  was  SPSS
3.0  for  Windows.
esults
ontrols
n  all  concentrations  considered,  none  of  the  negative  con-
rol  tubes  with  L.  operculata  showed  visible  turbidity  or
rowth  of  any  bacteria  strain.
All  bacterial  broth  and  all  alcoholic  controls  showed  vis-
ble  turbidity  and  speciﬁc  bacterial  growth  of  each  broth,
ithout  sample  contamination.
o
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Table  3  Calculation  of  dilutions  and  alcohol  strength  from  the  init
and with  alcoholic  strength  of  65%.
Concentrations  of
Luffa  operculata  (%)
Luffa  operculata
10%  (mL)
TSB  
0.2  0.2  9.8  
0.3 0.3  9.7  
0.4 0.4  9.6  
0.5 0.5  9.5  
1 1  9  
2 2  8  
TSB, Tryptic Soy Bean.All  negative,  positive  and  alcoholic  controls  were  per-
ormed  in  duplicate  for  all  samples,  having  conﬁrmed  their
esults.
icroorganisms
ll  tubes  containing  L.  operculata  at  concentrations  of  0.2%
nd  0.3%  and  with  S.  pyogenes,  S.  pneumoniae  and  S.  aureus
acterial  broth  showed  turbidity  after  a 24-h  incubation
eriod.  The  24-  and  48-h  seedings  conﬁrmed  the  presence
f  bacteria,  showing  growth  of  just  those  bacteria  tested,
hich  excluded  any  sample  contamination.
All  tubes  containing  L.  operculata  at  a  concentration
f  0.4%  and  with  S.  pyogenes  bacterial  broth  showed  no
ial  concentration  of  10%  alcoholic  extract  of  Luffa  operculata,
(mL)  Luffa
operculata  +  TSB  (mL)
Alcoholic
strength  (%)
10  1.30
10  1.95
10  2.60
10  3.25
10  6.50
10  13.00
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Table  4  Turbidity  and  seeding  results  on  bacterial  agents  for  Luffa  operculata  in  different  concentrations.
Agent  Concentration  Turbidity  (n  =  25)  24-  and  48-h
seedings  (n  =  25)
Streptococcus
pyogenes
Luffa  operculata
0.4%
25  Negatives  (100%)  24  Negatives  (96%)
1 Positive  (4%)
Kappa =  0  (p-value
not  calculated)
0  Positive  (0%)  0  Negative  (0%)
0 Positive  (0%)
Streptococcus
pneumoniae
Luffa operculata  0.4%
(Kappa  /=  0;  p  <  0.449)
8  Negatives  (32%) 3  Negatives  (12%)
5 Positives  (20%)
17 Positives  (68%)  0  Negative  (0%)
17  Positives  (68%)
Luffa operculata  0.5%
(Kappa  /=  0;  p  <  0.528)
18  Negatives  (72%)  12  Negatives  (48%)
6 Positives  (24%)
7 Positives  (28%)  0  Negative  (0%)
7 Positives  (28%)
Staphylococcus
aureus
Luffa operculata  1%
(Kappa  =  0  (p-value  not
calculated)
4  Negatives  (16%)  0  Negative  (0%)
4 Positives  (16%)
21 Positives  (84%)  0  Negative  (0%)
21  Positives  (84%)
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Mturbidity  after  a  24-h  incubation  period.  However,  among
those  25  samples  of  S.  pyogenes  (ATCC-19615  and  24  clinical
isolates)  tested,  a  clinical  isolate  (4%)  showed  bacterial
growth  in  24-  and  48-h  seedings  (Table  4).
Among  the  25  tubes  containing  L.  operculata  at  a  concen-
tration  of  0.4%  and  with  S.  pneumoniae  bacterial  broth
(ATCC-49619  and  24  clinical  isolates),  the  ATCC  sample  and
two  clinical  isolates  (12%)  showed  no  turbidity  after  a  24-h
incubation  period  and  no  bacterial  growth  in  24-  and  48-h
cultures.  Five  other  clinical  samples  (20%)  showed  no  tur-
bidity  after  a  24-h  incubation,  but  showed  growth  in  24-  and
48-h  cultures.  Seventeen  clinical  isolates  (68%)  showed  tur-
bidity  after  a  24-h  incubation  period  and  bacterial  growth
in  24-  and  48-h  cultures.  These  25  cultures  showed  growth
only  for  S.  pneumoniae, which  excluded  any  type  of  sam-
ple  contamination.  Statistical  analysis  showed  Kappa  /=  0
and  p  <  0.449,  indicating  a  moderately  suggestive  result  of
antimicrobial  response  (Table  4).
All  tubes  containing  L.  operculata  at  concentrations  of
0.4%  and  0.5%  and  with  S.  aureus  bacterial  broth  showed  tur-
bidity  after  a  24-h  incubation  period.  24-  and  48-h  cultures
conﬁrmed  the  presence  of  these  bacteria.
All  tubes  containing  L.  operculata  at  concentrations  of
0.5%;  1%  and  2%  and  with  S.  pyogenes  bacterial  broth  showed
no  turbidity  after  a  24-h  incubation  period  and  no  bacterial
growth  in  24-  and  48-h  cultures.
Among  the  25  tubes  containing  L.  operculata  at  a  concen-
tration  of  5%  and  with  S.  pneumoniae  bacterial  broth
(ATCC-49619  and  24  clinical  isolates),  the  ATCC  sample  and
11  clinical  isolates  (48%)  showed  no  turbidity  after  a  24-h
incubation  period,  or  bacterial  growth  in  48-h  cultures.  Six
other  clinical  isolates  (24%)  showed  no  turbidity  after  a  24-h
incubation  period,  but  with  growth  after  24-  and  48-h  cul-
tures.  Seven  clinical  isolates  (28%)  showed  turbidity  after
a  24-h  incubation  period  and  bacterial  growth  in  24-  and
48-h  cultures.  These  25  cultures  showed  growth  only  of  S.
pneumoniae, which  excluded  any  type  of  sample  contami-
nation.  Statistical  analysis  showed  Kappa  /=  0  and  p  <  0.528,
n
m
f
undicating  a  moderately  suggestive  result  of  antimicrobial
esponse  (Table  4).
The  test  tubes  containing  L.  operculata  at  concentrations
f  1%  and  2%  and  with  S.  pneumoniae  bacterial  broth  showed
o  turbidity  after  a  24-h  incubation  period  and  no  bacterial
rowth  in  24-  and  48-h  cultures.
Among  the  25  tubes  containing  L.  operculata  at  a  concen-
ration  of  1%  and  containing  S.  aureus  (ATCC-25923  and  24
linical  isolates),  the  ATCC  sample  and  three  clinical  isolates
16%)  showed  no  turbidity  after  a  24-h  incubation  period;
owever,  all  showed  growth  after  24-  and  48-h  cultures
Table  4).
The  tubes  containing  L.  operculata  at  a  concentration  of
%  and  with  S.  aureus  bacterial  broth  showed  no  turbidity
fter  a 24-h  incubation  period  and  no  bacterial  growth  in  24-
nd  48-h  cultures.
iscussion
xtract  choice
ne  of  the  major  difﬁculties  in  the  use  of  herbal  medicine
n  controlled  studies  is  the  lack  of  standardization  of  herbal
rugs.  None  of  the  experimental  studies  published  between
001  and  2010  had  the  same  method  of  obtaining  L.  opercu-
ata  extracts.4,11--13
Another  difﬁculty  for  the  use  of  plants  in  natura,  espe-
ially  when  it  comes  to  evaluating  the  antimicrobial  action
f  an  herbal  drug,  is  to  ensure  the  origin  of  the  material
nd  absence  of  contamination.  In  a  study  published  in  2001,
he  quality  of  L.  operculata  dried  fruits  from  the  Municipal
arket  of  São  Luiz  do  Maranhão  was  evaluated,  and  contami-
ation  of  all  samples  of  L.  operculata  fruits  acquired  in  this
arket  has  been  proven;  some  fruits  were  contaminated  by
ungi  and  some  by  bacteria,  making  them  unsuitable  for  its
se.15
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Aiming  to  avoid  the  presence  of  contaminated  fruits  that
ould  contaminate  the  samples  in  our  study,  as  well  as  to
nsure  that  the  same  extract  was  used  throughout  the  work,
e  chose  to  use  an  industrialized  alcoholic  extract  of  L.
perculata,  whose  access  was  available  for  replication  of
he  study,  if  necessary.
It  is  relevant  to  note  that  the  reproducibility  of  the
esearch  is  restricted  to  the  batch  speciﬁcally  used  in  this
tudy.  Depending  on  the  conditions  of  soil,  sunlight  and  rain-
all  index,  we  cannot  guarantee  that  other  batches  produced
n  other  seasons  or  with  origin  in  other  crops  would  have  the
ame  results  found  in  our  study.  It  is  important  to  ensure
ome  comparison  level  in  the  conduction  of  other  studies
sing  different  L.  operculata  extracts  at  the  same  concen-
rations  and  with  the  same  bacterial  agents.
oncentrations  used
ince  1960  a  few  articles  have  attempted  to  evaluate  the
echanisms  of  action  by  which  L.  operculata  acts  on  the
espiratory  epithelium,  and  also  to  prove  its  therapeutic  efﬁ-
acy  in  the  clinical  treatment  of  rhinosinusitis.12 The  authors
ould  not  identify  anything  that  would  establish  reliable
riteria  for  its  safe  use12 and  some  actually  reported  that
he  improper  use  of  this  herbal  product,  especially  at  high
oncentrations  of  L.  operculata, can  lead  to  a  worsening
f  sinonasal  conditions.4,6 Nevertheless,  some  clinical  and
xperimental  studies  list  concentrations  of  0.5%  and  1%  for
he  treatment  of  rhinosinusitis.13,16,17
As  we  found  no  references  on  antimicrobial  activity  of
.  operculata  in  the  literature  before  2008,  when,  in  a
ingle  study,  only  one  screening  procedure  with  different
acteria  and  fungi  was  conducted,18 we  chose  to  start  our
nvestigation  with  a  concentration  of  1%,  the  same  level
resent  in  this  commercial  extract,  released  by  ANVISA  and
ested  in  most  studies  cited  in  the  literature.11,13,17 We  used
wice  the  recommended  concentration  (2%),  thus  setting
 limit  to  this  antimicrobial  activity,  without  approaching
D507,16 or  causing  an  increase  of  its  deleterious  effects
o  the  mucosa.  Finally,  other  concentrations  (0.2%;  0.3%;
.4%  and  0.5%)  were  evaluated,  in  an  attempt  to  establish
 minimum  concentration  in  which  L.  operculata  exhibited
n  antimicrobial  effect,  so  as  to  minimize  any  side  effects.
acterial  agents
ll  tubes  containing  L.  operculata  at  concentrations  of  0.2%
nd  0.3%  and  with  S.  pyogenes,  S.  pneumoniae  and  S.  aureus
acterial  broth  showed  turbidity  after  a  24-h  incubation
eriod,  indicating  bacterial  growth  in  these  concentrations,
nd  hence,  no  antimicrobial  action  to  these  microorganisms.
All  tubes  containing  L.  operculata  at  a  concentration
f  0.4%  and  with  S.  pyogenes  bacterial  broth  showed  no
urbidity  after  a  24-h  incubation  period,  demonstrating
ntimicrobial  activity  for  this  agent,  in  this  concentration.
he  absence  of  visual  turbidity  per  se  led  to  the  conclu-
ion  that,  at  a  concentration  around  0.4%,  it  was  possible  to
etermine  MIC  for  S.  pyogenes.
Considering  that  the  absence  of  visual  turbidity,  con-
rmed  by  an  absence  of  growth  in  24-  and  48-h  cultures,  only
ccurred  in  those  tubes  with  L.  operculata  at  concentrations
i
d
w
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reater  than  0,5%,  it  was  inferred  that,  with  concentrations
round  this  level,  MBC  of  these  agents  can  be  established.
Some  samples  containing  L.  operculata  at  concentrations
f  0.4%  and  0.5%  and  with  S.  pneumoniae  bacterial  broth,
howed  no  medium  turbidity.  However,  the  fact  that  some
amples  presented  bacterial  growth  in  the  cultures  con-
rmed  that,  with  a  concentration  around  0.4%  or  0.5%,  we
an  establish  MIC  for  S.  pneumoniae, in  the  same  line  as  for
.  pyogenes.
At  L.  operculata  concentrations  higher  than  1%,  neither
urbidity  in  tubes  containing  S.  pneumoniae  nor  bacterial
rowth  in  24-  and  48-h  cultures  was  perceived;  however,
onsidering  that  no  intermediate  concentrations  between
.5%  and  1%  were  tested,  we  cannot  conclude  that  MBC
or  S.  pneumoniae  is  equal  to  1%.  It  may  be  that,  at  some
oncentration  between  0.5%  and  1%,  the  killing  of  all  tested
acteria  occurs,  and  in  order  for  this  to  happen,  clinical
tudies  with  a greater  L.  operculata  concentration  variety
ould  be  needed  to  establish  its  MBC.
Some  tubes  containing  L.  operculata  at  a  concentration
f  1%  and  with  S.  aureus  bacterial  broth  showed  no  visual
urbidity  after  the  24-h  reading,  suggesting  that,  at  this
oncentration,  L.  operculata  showed  antimicrobial  activity
or  this  agent,  thereby  establishing  its  MIC.  Only  at  a  concen-
ration  of  2%  there  was  no  turbidity  and  no  bacterial  growth
n  24-  and  48-h  cultures;  however,  as  also  occurred  with  S.
neumoniae,  we  cannot  guarantee  that  this  concentration
epresents  its  MBC.  The  lack  of  intermediate  concentrations
etween  1%  and  2%  is  no  guarantee  that  a  value  higher  than
%  and  lower  than  2%  also  may  be  able  to  eradicate  all  S.
ureus  organisms  (Table  5).
In  spite  of  being  Gram-positive  cocci,  S.  pyogenes,  S.
neumoniae  and  S.  aureus  showed  different  susceptibil-
ty  proﬁles,  when  in  a  milieu  containing  L.  operculata.
ower  concentrations  of  around  0.5%  were  able  to  kill  all  S.
yogenes  organisms,  while  S.  pneumoniae  organisms  were
radicated  only  at  a  concentration  of  1%;  as  for  S.  aureus,
ts  eradication  occurred  only  at  a  concentration  of  2%.  This
esponse  to  the  presence  of  L.  operculata  was  equivalent
o  the  response  of  these  microorganisms  to  conventional
ntibiotics.  There  are  multiple  mechanisms  by  which  these
acteria  develop  resistance  to  antibiotics.
S.  pneumoniae, for  example,  has  a capsule  that  impairs
he  action  of  antimicrobial  agents  on  its  cell  wall.  Usually,
his  bacterium  is  more  resistant  to  antibiotics  than  S.  pyo-
enes. On  the  other  hand,  S.  aureus  has  a  greater  ability
o  generate  bacterial  resistance  than  those  microorganisms
reviously  cited,  in  part  because  it  is  a  high  beta-lactamase
nducer.
tudy  limitations
he  paucity  of  studies  on  the  antimicrobial  activity  of  L.
perculata  made  it  difﬁcult  to  ﬁnd  references  for  the  dis-
ussion  of  our  study.  The  only  study  with  an  antimicrobial
ctivity  screening  for  some  ATCC  strains  of  different  bacteria
lso  found  for  S.  aureus  at  MIC  =  100  mg/mL.18 In  our  study,  as
n  the  previous  study,  we  evaluated  the  ATCC-25923  strain,
emonstrating  its  MIC  at  a  concentration  of  1%,  together
ith  three  other  clinical  isolates.  The  other  21  clinical  iso-
ates  tested  showed  visual  turbidity  after  a  24-h  culture  and
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Table  5  Presence  or  absence  of  bacterial  growth  in  different  concentrations  of  Luffa  operculata  extract.
Bacteria  Concentrations  of  Luffa  operculata
0.2%  0.3%  0.4%  0.5%  1%  2%
Streptococcus  pyogenes  +  +  +  −  −  −
Streptococcus  pneumoniae +  +  +  +  −  −
Staphylococcus  aureus +  +  +  +  +  −
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R+, presence of bacteria (turbidity or seeding-positive); −, absenc
bacterial  growth  after  24-  and  48-h  cultures,  not  replicat-
ing  the  results  of  the  ATCC  sample.  The  lack  of  studies  with
extracts  at  intermediate  concentrations  between  0.5%  and
1%  does  not  allow  us  to  state  that  its  MIC  is  1%,  but  allows  us
to  deduce  that  MIC  may  be  situated  between  0.5%  and  1%.
Likewise,  an  MBC  for  S.  aureus  also  cannot  be  established,
but  we  can  state  that,  for  these  samples  used  in  our  study,
MBC  lies  at  concentrations  of  L.  operculata  between  1%  and
2%.
No  previous  study  has  evaluated  the  antimicrobial  activ-
ity  of  L.  operculata  against  S.  pyogenes  or  S.  pneumoniae.
It  became  clear  in  our  study  that  S.  pyogenes  samples  were
more  susceptible  to  the  antimicrobial  action  of  L.  opercu-
lata,  compared  to  S.  pneumoniae  samples,  and  the  latter
organism,  in  turn,  was  more  susceptible  than  S.  aureus.
It  is  important  to  note  that  a  number  of  substances,  such
as  cucurbitacines  B  and  D,  glycosides,  saponins,  free  sterols,
organic  acids  and  phenols,  were  isolated  from  the  phyto-
chemical  analysis  of  L.  operculata.13,16,19 While  a  number
of  substances  exhibit  therapeutic  effects,  others  may  have
toxic  effects,  leading  even  to  a  worsening  of  the  clinical
presentation  upper  airway  infections.4
Thus,  even  with  the  promising  antimicrobial  effect  of
this  herbal  medicine,18 further  studies  should  be  conducted
with  the  aim  to  establish  which  of  these  components  have  a
therapeutic  effect  and  what  are  the  most  appropriate  con-
centrations,  so  that  its  use  does  not  cause  more  harm  than
good.  These  studies  should  seek  to  recognize  and  separate
the  therapeutic  and  toxic  components  of  L.  operculata, so
one  can  accept  or  discard  its  use  in  the  treatment  of  upper
airway  inﬂammatory  and  infectious  conditions.4,9,11--13
Considerations  for  the  future
Many  studies  have  been  conducted  to  elucidate  the  thera-
peutic  properties  of  L.  operculata. The  task  of  establishing
the  tenuous  relationship  between  toxicity  and  tractability  is
the  challenge  to  be  confronted.  The  ﬁnding  of  an  antimi-
crobial  action  in  this  herbal  agent  can  be  of  great  value
in  the  therapeutic  arsenal  against  upper  airway  diseases,
considering  that,  every  day,  mechanisms  of  bacterial  resis-
tance  increase  the  complication  in  the  treatment  of  these
diseases.
It  is  a  fact  that  herbal  medicines  present  variations  in
their  characteristics  and  also  exhibit  changes  in  their  compo-
nents,  depending  on  variations  in  the  composition  of  the  soil,
rainfall  index  and  seasonality  of  their  harvest;  this  results  in
an  ever  different  composition  having  unique  characteristics
that  make  it  difﬁcult  to  induce  bacterial  resistance.acteria (turbidity or seeding-negative).
From  the  moment  of  the  establishment  of  a  safe  dose
f  L.  operculata  for  use  in  the  oral  cavity,  its  antimicrobial
ffect  against  S.  pyogenes  could  be  of  great  importance,
n  creating  an  oral  spray  for  prophylaxis  of  rheumatic  fever.
atients  with  a  positive  rapid  test  and  no  signs  or  very  severe
ymptoms  could  use  this  spray,  to  eradicate  the  bacterial
gent  without  use  of  systemic  antibiotics.
The  same  can  be  said  for  the  treatment  of  sinonasal  dis-
ases,  where  the  presence  of  bioﬁlm  is  proved.  The  caustic
nd  detergent  effects  of  this  herbal  drug,  through  the  action
f  its  cucurbitacines  and  saponins  (if  their  side  effects  are
ontrolled)  could,  in  low  doses,  be  useful  in  the  destruction
f  polysaccharides’  structure,  thus  facilitating  the  action  of
n  associated  antibiotic  to  resolve  these  diseases.
It  is  important  that  we  continue  searching  for  information
bout  these  and  other  herbal  remedies,  in  an  attempt  to  ﬁnd
olutions  to  problems  that  arise  every  day,  and  that  often
esult  in  failure  with  the  resources  currently  available.
onclusion
.  operculata  extract  showed  promising  antimicrobial
ctivity  in  vitro  against  the  causative  agents  of  upper
irway  bacterial  infections  tested  in  this  study,  both  in
hose  microorganisms  with  known  susceptibility  and  pro-
le  (ATCC),  and  in  those  of  clinical  origin.  This  can  be  an
mportant  step  in  creating  new  drugs  to  treat  these  diseases.
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